Yahoo Finance • 6 days ago
Three of the five stocks to watch are part of the artificial intelligence trade, including chip company Nvidia. Continue Reading View Comments... Full story
Yahoo Finance • 12 days ago
Key Points Terns Pharmaceuticals and Rhythm Pharmaceuticals are developing weight loss medicines. Terns Pharmaceuticals has an upcoming data readout for a promising oral candidate. Rhythm Pharmaceuticals is targeting label expansions for... Full story
Yahoo Finance • last month
BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today anno... Full story
Yahoo Finance • last month
[Open notebook with review. Feedback collection and personal reflection.] designer491/iStock via Getty Images Rhythm Pharmaceuticals (NASDAQ:RYTM [https://seekingalpha.com/symbol/RYTM]) announced that U.S. and EU regulators have accepted... Full story
Yahoo Finance • last month
(RTTNews) - Rhythm Pharmaceuticals, Inc. (RYTM) announced that the U.S. Food and Drug Administration has accepted for filing the company's supplemental New Drug Application or sNDA for setmelanotide seeking approval for the treatment of co... Full story
Yahoo Finance • last month
– U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 -- – European Medicines Agency accepts and validates submission for Type II variation MAA for setmelanotide to tre... Full story
Yahoo Finance • 2 months ago
Boston, MA - Christopher Paul German, Corporate Controller & CAO at Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), sold 1,500 shares of common stock on August 12, 2025, according to a Form 4 filing with the Securities and Exchange Commission.... Full story
Yahoo Finance • 2 months ago
Rhythm Pharmaceuticals (NASDAQ:RYTM), a $6.4 billion market cap biotech company with impressive gross profit margins of 89%, saw Chief Financial Officer Hunter C. Smith sell 28,088 shares of common stock on August 12 and 13, according to a... Full story
Yahoo Finance • 2 months ago
Rhythm Pharmaceuticals (NASDAQ:RYTM), a $6.5 billion market cap biotech company whose stock has surged 112% over the past year, reported that Chief Technical Officer Joseph Shulman sold 3,984 shares of common stock on August 11, 2025, at p... Full story
Yahoo Finance • 2 months ago
Investing.com - Rhythm Pharma (NASDAQ: RYTM) reported second quarter EPS of $-0.75, $0.08 worse than the analyst estimate of $-0.67. Revenue for the quarter came in at $48.5M versus the consensus estimate of $43.75M. Rhythm Pharma’s sto... Full story
Yahoo Finance • 2 months ago
Introduction & Market Context Rhythm Pharmaceuticals (NASDAQ:RYTM) presented its second quarter 2025 financial results and business update on August 5, 2025, highlighting strong revenue growth and significant clinical progress for its obe... Full story
Yahoo Finance • 2 months ago
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM [https://www.chartmill.com/stock/quote/RYTM/profile]) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The company's revenue exceeded... Full story
Yahoo Finance • 2 months ago
* Rhythm Pharmaceuticals (NASDAQ:RYTM [https://seekingalpha.com/symbol/RYTM]) is scheduled to announce Q2 earnings results on Tuesday, August 5th, before market open. * The consensus EPS Estimate is -$0.67 [https://seekingalpha.com/sym... Full story
Yahoo Finance • 2 months ago
Pamela J. Cramer, Chief Human Resources Officer at Rhythm Pharmaceuticals, INC. (NASDAQ:RYTM), sold 1,520 shares of common stock on July 29 at a price of $85.93, totaling approximately $130,613. The transaction comes as the $5.6 billion ma... Full story
Yahoo Finance • 2 months ago
Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals (NASDAQ:RYTM), sold 1,520 shares of common stock on July 29, 2025, at a price of $85.93, for a total value of $130,613. The transaction comes as the $5.6 billion mar... Full story
Yahoo Finance • 2 months ago
BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today anno... Full story
Yahoo Finance • 3 months ago
Investing.com - Canaccord Genuity raised its price target on Rhythm Pharmaceuticals (NASDAQ:RYTM) to $105.00 from $92.00 on Friday, while maintaining a Buy rating on the stock. The company, now valued at nearly $6 billion, has seen its sha... Full story
Yahoo Finance • 3 months ago
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelanotide, including with prior use or concom... Full story
Yahoo Finance • 3 months ago
Investing.com -- Markets concluded the week with a notable shift in sentiment. After reaching record highs earlier, U.S. stocks closed lower on Friday, impacted by macroeconomic concerns. Here are Investing.com’s stocks of the week. Core... Full story
Yahoo Finance • 3 months ago
Investing.com - Oppenheimer has increased its price target on Rhythm Pharmaceuticals (NASDAQ:RYTM) to $110.00 from $76.00 while maintaining an Outperform rating on the stock. The company, now valued at $5.66 billion, has seen its shares su... Full story